within Pharmacolibrary.Drugs.ATC.R;

model R05DB09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0 / 1000000,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Oxeladin is a centrally acting, non-opioid cough suppressant previously used for the symptomatic treatment of non-productive cough. It is a cough medicine that was historically marketed in several countries but is currently not widely approved or used, in part due to limited evidence and the availability of newer alternatives.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed pharmacokinetic data (such as bioavailability, clearance, volume of distribution, or compartmental modeling) are available for oxeladin in the published literature as of 2024.</p><h4>References</h4><ol><li><p>Lartigue-Mattei, C, et al., &amp; Aiache, JM (1995). Determination of oxeladin in human plasma by gas chromatography--mass spectrometry. <i>Biomedical chromatography : BMC</i> 9(1) 32â€“35. DOI:<a href=&quot;https://doi.org/10.1002/bmc.1130090107&quot;>10.1002/bmc.1130090107</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7734931/&quot;>https://pubmed.ncbi.nlm.nih.gov/7734931</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R05DB09;
